Antagonists of HMG1 for treating inflammatory conditions
AssigneeNorth Shore-Long Island Jewish Research Institute
InventorsKevin J. Tracey, Haichao Wang
Life of this patent
Estimating the term…
Abstract
There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
Claims7
A method for treating a condition characterized by activation of the inflammatory cytokine cascade, comprising administering an effective amount of an antibody that specifically binds an HMG1 protein, wherein said antibody inhibits HMG1-mediated activation of the inflammatory cytokine cascade.
A method for treating sepsis, comprising administering an effective amount of an antibody that specifically binds an HMG1 protein and inhibits HMG1-mediated activation of the inflammatory cytokine cascade.
Dependencies are inferred from the claim text.